ViroGates ASOCSE:VIRO 46 Days Payable is 279.61 as of Mar. 2026, which is 25% below its 10-year median of 372.54. GuruFocus rates OCSE:VIRO with a GF Score™ of 46/100 and a GF Value™ of kr6.78 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 795 Medical Devices & Instruments companies, ViroGates AS ranks better than 83.02% on this metric.
The historical rank and industry rank for ViroGates AS's Days Payable or its related term are showing as below:
OCSE:VIRO'
s Days Payable Range Over the Past 10 Years
Min: 68.52 Med: 372.54 Max: 1390.28
Current: 183.29
During the past 10 years, ViroGates AS's highest Days Payable was 1390.28. The lowest was 68.52. And the median was 372.54.
OCSE:VIRO's Days Payable is ranked better than 83.02% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs OCSE:VIRO: 183.29
ViroGates AS's Days Payable
increased
from Mar. 2025 (53.80) to Mar. 2026 (279.61).
It may suggest that ViroGates ASdelayed paying its suppliers.
ViroGates AS Days Payable Related Terms
ViroGates AS Days Payable Historical Data
* Premium members only.
The historical data trend for ViroGates AS's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:VIRO vs ABT, SYK, MDT: Days Payable Comparison
For the Medical Devices subindustry, ViroGates AS's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ViroGates AS Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ViroGates AS's Days Payable distribution charts can be found below:
* The bar in red indicates where ViroGates AS's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
ViroGates AS's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ViroGates AS (OCSE:VIRO) has a Days Payable of 279.61 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ViroGates AS and its competitors. This is 25% below median its historical median of 372.54. Over the past decade, ViroGates AS's Days Payable has ranged from 68.52 to 1,390.28. According to the industry distribution chart, ViroGates AS ranks #135 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 17%.
Is ViroGates AS's Days Payable too high?
ViroGates AS's current Days Payable of 279.61 is 25% below median its 10-year median of 372.54. Over the past 10 years, this metric has ranged from a low of 68.52 to a high of 1,390.28. The Medical Devices & Instruments industry median Days Payable is 68.07. ViroGates AS's value of 279.61 is 310.8% above this industry median. Based on the distribution chart, ViroGates AS ranks #135 out of 795 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, ViroGates AS has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ViroGates AS's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ViroGates AS ranks #135 out of 795 companies for Days Payable. This places ViroGates AS in the top 17% of its industry — outperforming the majority of peers. The industry median Days Payable is 68.07. ViroGates AS's value of 279.61 is 310.8% above this benchmark. Historically, ViroGates AS's own Days Payable has ranged from 68.52 to 1,390.28 over the past decade. While the company's 10-year median is 372.54 vs. the industry median of 68.07, ViroGates AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ViroGates AS's current Days Payable of 279.61 is 310.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ViroGates AS and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ViroGates AS's current Days Payable is 279.61, which is 25% below median its own 10-year median of 372.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViroGates AS stock overvalued right now?
Based on GuruFocus' analysis, ViroGates AS (OCSE:VIRO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr6.78, compared to a current price of kr10.90 — trading 60.8% above its estimated fair value. The current Days Payable is 279.61, which is 25% below median its 10-year median of 372.54 and 310.8% above the Medical Devices & Instruments industry median of 68.07. ViroGates AS's overall GF Score™ is 46/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For ViroGates AS (OCSE:VIRO), the current Days Payable is 279.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ViroGates AS (OCSE:VIRO) Overvalued in 2026?
Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued.
The current stock price of kr10.90 is trading 60.8% above its estimated GF Value™ of kr6.78.
GuruFocus considers ViroGates AS to be Significantly Overvalued.
Key valuation signals for OCSE:VIRO:
Days Payable: 279.61 (25% below median its 10-year median of 372.54)
GF Value™: kr6.78 vs. price of kr10.90 (60.8% above fair value)
Industry Position: 310.8% above the Medical Devices & Instruments median (#135 of 795)
No single metric tells the full story. See the OCSE:VIRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
46GF Score
Get the complete analysis for OCSE:VIRO
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:VIRO has been successfully added to your 
